Switch theme
Sign up to access all valuation multiples
Salus is a Slovenia-based company engaged in the wholesale and distribution of medical products. It offers medicines, medical devices, medical supplies, dietary supplements, cosmetics to hospitals, pharmacies, and other customers.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Salus has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Salus achieved revenue of $730M and an EBITDA of $28.8M.
Salus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Salus valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $674M | $730M | XXX | XXX | XXX |
| Gross Profit | $60.5M | $67.7M | XXX | XXX | XXX |
| Gross Margin | 9% | 9% | XXX | XXX | XXX |
| EBITDA | $22.0M | $28.8M | XXX | XXX | XXX |
| EBITDA Margin | 3% | 4% | XXX | XXX | XXX |
| Net Profit | $14.7M | $11.6M | XXX | XXX | XXX |
| Net Margin | 2% | 2% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 13, 2025, Salus's stock price is EUR 2400 (or $2700).
Salus has current market cap of EUR 253M (or $284M), and EV of EUR 254M (or $286M).
See Salus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $286M | $284M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 13, 2025, Salus has market cap of $284M and EV of $286M.
Salus's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Salus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Salus and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $286M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | XXX | XXX |
| P/E | 19.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 31.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSalus's NTM/LTM revenue growth is n/a
Salus's revenue per employee for the last fiscal year averaged $1.8M, while opex per employee averaged n/a for the same period.
Over next 12 months, Salus's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Salus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Salus and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 0% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Salus acquired XXX companies to date.
Last acquisition by Salus was XXXXXXXX, XXXXX XXXXX XXXXXX . Salus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Salus founded? | Salus was founded in 1969. |
| Where is Salus headquartered? | Salus is headquartered in Slovenia. |
| How many employees does Salus have? | As of today, Salus has 413 employees. |
| Is Salus publicy listed? | Yes, Salus is a public company listed on LJU. |
| What is the stock symbol of Salus? | Salus trades under SALR ticker. |
| When did Salus go public? | Salus went public in 1999. |
| Who are competitors of Salus? | Similar companies to Salus include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Salus? | Salus's current market cap is $284M |
| What is the current revenue growth of Salus? | Salus revenue growth between 2023 and 2024 was 8%. |
| Is Salus profitable? | Yes, Salus is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
